Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 4Phase 1 3Phase 4 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Head & Neck 1

Conditions

Salivary Gland Neoplasms 1Prostatic Neoplasms 1High-Risk Localized Prostate Cancer 1Granulosa cell tumor of the ovary 1

Interventions

Specimen Handling 176Magnetic Resonance Spectroscopy 138Biopsy 102pembrolizumab 81Carboplatin 79Cisplatin 71Nivolumab 65Cyclophosphamide 64Paclitaxel 54Radiotherapy 48Gemcitabine 43durvalumab 39Doxorubicin 35Bevacizumab 34Fluorouracil 33venetoclax 32Dexamethasone 31Rituximab 30atezolizumab 29Radiation 29Capecitabine 28Lenalidomide 27Etoposide 27Prednisone 26Oxaliplatin 26Injections 26Pemetrexed 25Docetaxel 25olaparib 23fludarabine 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × darolutamide × 30 days × Clear all
NCT04070209 2026-05-27

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2 Active not recruiting
66 enrolled
Genitourinary

Prostatic Neoplasms

NCT05669664 2026-05-13

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
21 enrolled
Head & Neck

Salivary Gland Neoplasms

NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

NCT07450599 2026-05-13

CHINANEO

Bayer

Phase 2 Recruiting
250 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡